Free Trial
NASDAQ:SNGX

Soligenix Q4 2024 Earnings Report

Soligenix logo
$3.06 -0.08 (-2.39%)
As of 10:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Soligenix EPS Results

Actual EPS
-$1.14
Consensus EPS
-$0.95
Beat/Miss
Missed by -$0.19
One Year Ago EPS
-$12.66

Soligenix Revenue Results

Actual Revenue
$0.20 million
Expected Revenue
$0.20 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Soligenix Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 20, 2025
Conference Call Time
8:00PM ET

Upcoming Earnings

Soligenix's Q3 2025 earnings is scheduled for Friday, November 14, 2025, with a conference call scheduled on Monday, November 10, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Soligenix Earnings Headlines

This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
Small Cap Stocks To Follow Today - August 18th
Soligenix (NASDAQ:SNGX) Cut to Strong Sell at Wall Street Zen
Why Is Soligenix Stock Soaring On Monday?
See More Soligenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Soligenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Soligenix and other key companies, straight to your email.

About Soligenix

Soligenix (NASDAQ:SNGX), Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

View Soligenix Profile

More Earnings Resources from MarketBeat